| 利妥昔单抗运用于原发中枢神经系统淋巴瘤的价值 |
| |
| 引用本文： | 李文瑜,陈菲莉. 利妥昔单抗运用于原发中枢神经系统淋巴瘤的价值[J]. 循证医学, 2018, 18(2): 83-84. DOI: 10.12019/j.issn.1671-5144.2018.02.007 |
| |
| 作者姓名： | 李文瑜 陈菲莉 |
| |
| 作者单位： | 广东省人民医院肿瘤中心淋巴瘤科、广东省医学科学院, 广州 510080 |
| |
| 摘 要： |
|
| 关 键 词： | 原发中枢神经系统淋巴瘤 利妥昔单抗 |
Rituximab in The Treatment of Primary Central Nervous System Lymphoma |
| |
| LI Wen-yu,CHEN Fei-li. Rituximab in The Treatment of Primary Central Nervous System Lymphoma[J]. The Journal of Evidence-Based Medicine, 2018, 18(2): 83-84. DOI: 10.12019/j.issn.1671-5144.2018.02.007 |
| |
| Authors: | LI Wen-yu CHEN Fei-li |
| |
| Affiliation: | Authors’ address： Lymphoma Department, Cancer Center, Guangdong General Hospital,Guangdong Academy of Medical Sciences, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | primary central nervous system lymphoma Rituximab |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
|
